



# A PIONEER DIAGNOSTIC CENTRE

**NAME** : Mrs. MINAKSHI

AGE/ GENDER : 24 YRS/FEMALE **PATIENT ID** : 1702332

**COLLECTED BY** REG. NO./LAB NO. : 122412180012

REFERRED BY **REGISTRATION DATE** : 18/Dec/2024 12:52 PM BARCODE NO. : 12506203 **COLLECTION DATE** : 18/Dec/2024 12:56PM

CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 18/Dec/2024 03:29PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

**Value** Unit **Biological Reference interval Test Name** 

# **ENDOCRINOLOGY**

## THYROID FUNCTION TEST: TOTAL

TRIIODOTHYRONINE (T3): SERUM 0.35 - 1.931.27 ng/mL by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)

THYROXINE (T4): SERUM 8.62 μgm/dL 4.87 - 12.60

by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)

THYROID STIMULATING HORMONE (TSH): SERUM μIU/mL 0.35 - 5.501.71 by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)

3rd GENERATION, ULTRASENSITIVE

### INTERPRETATION:

TSH levels are subject to circadian variation, reaching peak levels between 2-4 a.m and at a minimum between 6-10 pm. The variation is of the order of 50%. Hence time of the day has influence on the measured serum TSH concentrations. TSH stimulates the production and secretion of the metabolically active hormones, thyroxine (T4) and triliodothyronine (T3). Failure at any level of regulation of the hypothalamic-pituitary-thyroid axis will result in either underproduction (hypothyroidism) or overproduction(hyperthyroidism) of T4 and/or T3.

CLINICAL CONDITION	T3	T4	TSH
Primary Hypothyroidism:	Reduced	Reduced	Increased (Significantly)
Subclinical Hypothyroidism:	Normal or Low Normal	Normal or Low Normal	High
Primary Hyperthyroidism:	Increased	Increased	Reduced (at times undetectable)
Subclinical Hyperthyroidism:	Normal or High Normal	Normal or High Normal	Reduced

- 1. T3 and T4 circulates in reversibly bound form with Thyroid binding globulins (TBG), and to a lesser extent albumin and Thyroid binding Pre Albumin so conditions in which TBG and protein levels alter such as pregnancy, excess estrogens, androgens, anabolic steroids and glucocorticoids may falsely affect the T3 and T4 levels and may cause false thyroid values for thyroid function tests
- 2. Normal levels of T4 can also be seen in Hyperthyroid patients with :T3 Thyrotoxicosis, Decreased binding capacity due to hypoproteinemia or ingestion of certain drugs
- 3. Serum T4 levels in neonates and infants are higher than values in the normal adult, due to the increased concentration of TBG in neonate serum.
- 4. TSH may be normal in central hypothyroidism, recent rapid correction of hyperthyroidism or hypothyroidism, pregnancy, phenytoin therapy.

TRIIODOTH	(RONINE (T3)	THYROX	INE (T4)	THYROID STIMUI	ATING HORMONE (TSH)
Age	Refferance Range (ng/mL)	Age	Refferance Range (µg/dL)	Age	Reference Range ( μΙU/mL)
0 - 7 Days	0.20 - 2.65	0 - 7 Days	5.90 - 18.58	0 - 7 Days	2.43 - 24.3
7 Days - 3 Months	0.36 - 2.59	7 Days - 3 Months	6.39 - 17.66	7 Days - 3 Months	0.58 - 11.00
3 - 6 Months	0.51 - 2.52	3 - 6 Months	6.75 – 17.04	3 Days – 6 Months	0.70 - 8.40
6 - 12 Months	0.74 - 2.40	6 - 12 Months	7.10 – 16.16	6 – 12 Months	0.70 - 7.00



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)





# A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

**NAME** : Mrs. MINAKSHI

AGE/ GENDER : 24 YRS/FEMALE **PATIENT ID** :1702332

**COLLECTED BY** REG. NO./LAB NO. : 122412180012

REFERRED BY **REGISTRATION DATE** : 18/Dec/2024 12:52 PM BARCODE NO. : 12506203 **COLLECTION DATE** : 18/Dec/2024 12:56PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 18/Dec/2024 03:29PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name			Value	Unit	t	Biological Reference interval
1 - 10 Years	0.92 - 2.28	1 - 10 Years	6.00 - 13.80	1 – 10 Years	0.60 - 5.50	
11- 19 Years	0.35 - 1.93	11 - 19 Years	4.87- 13.20	11 – 19 Years	0.50 - 5.50	
> 20 years (Adults)	0.35 - 1.93	> 20 Years (Adults)	4.87 - 12.60	> 20 Years (Adults)	0.35- 5.50	
	RECOM	IMENDATIONS OF TSH LE	VELS DURING PRE	GNANCY ( µIU/mL)		
1st Trimester		0.10 - 2.50				
	2nd Trimester			0.20 - 3.00		
3rd Trimester				0.30 - 4.10		

### **INCREASED TSH LEVELS:**

- 1. Primary or untreated hypothyroidism may vary from 3 times to more than 100 times normal depending upon degree of hypofunction.
- 2. Hypothyroid patients receiving insufficient thyroid replacement therapy.
- 3. Hashimotos thyroiditis
- 4.DRUGS: Amphetamines, iodine containing agents & dopamine antagonist.
- 5. Neonatal period, increase in 1st 2-3 days of life due to post-natal surge

## **DECREASED TSH LEVELS:**

- 1. Toxic multi-nodular goiter & Thyroiditis.
- 2. Over replacement of thyroid hormone in treatment of hypothyroidism.
- 3. Autonomously functioning Thyroid adenoma
- 4. Secondary pituitary or hypothalamic hypothyroidism
- 5. Acute psychiatric illness
- 6. Severe dehydration.
- 7.DRUGS: Glucocorticoids, Dopamine, Levodopa, T4 replacement therapy, Anti-thyroid drugs for thyrotoxicosis.

8. Pregnancy: 1st and 2nd Trimester



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)





# A PIONEER DIAGNOSTIC CENTRE

**■** 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

**NAME** : Mrs. MINAKSHI

AGE/ GENDER : 24 YRS/FEMALE **PATIENT ID** : 1702332

**COLLECTED BY** REG. NO./LAB NO. : 122412180012

REFERRED BY **REGISTRATION DATE** : 18/Dec/2024 12:52 PM BARCODE NO. : 12506203 **COLLECTION DATE** : 18/Dec/2024 12:56PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 18/Dec/2024 10:06PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Value Unit **Biological Reference interval Test Name** 

### **LUTEINISING HORMONE (LH)**

LUTEINISING HORMONE (LH): SERUM mIU/mL MALES: 0.57 - 12.07

by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY) FOLLICULAR PHASE: 1.80 -

11.78

MID-CYCLE PEAK: 7.59 - 89.08 LUTEAL PHASE: 0.56 - 14.0

POST MENOPAUSAL WITHOUT HRT: 5.16 - 61.99

**INTERPRETATION:** 

1. Luteinizing hormone (LH) is a glycoprotein hormone consisting of 2 non covalently bound subunits (alpha and beta). Gonadotropin-releasing hormone from the hypothalamus controls the secretion of the gonadotropins, FSH and LH, from the anterior pituitary.

2. In both males and females, LH is essential for reproduction. In females, the menstrual cycle is divided by a mid cycle surge of both LH and FSH into a follicular phase and a luteal phase.

3. This "LH surge" triggers ovulation thereby not only releasing the egg, but also initiating the conversion of the residual follicle into a corpus luteum that, in turn, produces progesterone to prepare the endometrium for a possiblei mplantation.

4. LH supports thecal cells in the ovary that provide androgens and hormonal precursors for estradiol production. LH in males acts on testicular interstitial cells of Leydig to cause increased synthesis of testosterone.

The test is useful in the following situations:

1. An adjunction the ovaluation of monetrial irregularities.

- 1. An adjunctin the evaluation of menstrual irregularities.
- 2. Evaluating patients with suspected hypogonadism
- 3. Predicting ovulation & Evaluating infertility
- 4. Diagnosing pituitary disorders
- 5. In both males and females, primary hypogonadism results in an elevation of basal follicle-stimulating hormone and luteinizing hormone levels

## **FSH AND LH ELEVTED IN:**

- 1. Primary gonadal failure
- 2. Complete testicular feminization syndrome
- 3. Precocious puberty (either idiopathic or secondary to a central nervous system lesion)
- 4. Menopause
- 5. Primary ovarian hypo dysfunction in females
- 6. Polycystic ovary disease in females
- 7. Primary hypogonadism in males

# LH IS DECŘEÁSEĎ IN:

- 1. Primary ovarian hyper function in females
- Primary hypergonadism in males

1.FSH and LH are both decreased in failure of the pituitary or hypothalamus.

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)



# A PIONEER DIAGNOSTIC CENTRE

**NAME** : Mrs. MINAKSHI

AGE/ GENDER : 24 YRS/FEMALE **PATIENT ID** :1702332

**COLLECTED BY** REG. NO./LAB NO. : 122412180012

REFERRED BY **REGISTRATION DATE** : 18/Dec/2024 12:52 PM BARCODE NO. : 12506203 **COLLECTION DATE** : 18/Dec/2024 12:56PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 18/Dec/2024 10:30PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

**Value** Unit **Biological Reference interval Test Name** 

### FOLLICLE STIMULATING HORMONE (FSH)

FOLLICLE STIMULATING HORMONE (FSH): SERUM mIU/mL FEMALE FOLLICULAR PHASE:

by CLIA (CHEMILUMINESCENCE IMMUNOASSAY) 3.03 - 8.08

FEMALE MID-CYCLE PEAK: 2.55

- 16.69

FEAMLE LUTEAL PHASE: 1.38 -

5.47

FEMALE POST-MENOPAUSAL:

26.72 - 133.41 MALE: 0.95 - 11.95

**INTERPRETATION:** 

1. Gonadotropin-releasing hormone from the hypothalamus controls the secretion of the gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary.

2. The menstrual cycle is divided by a midcycle surge of both FSH and LH into a follicular phase and a luteal phase.

3. FSH appears to control gametogenesis in both males and females.

The test is useful in the following settings:

- 1. An adjunct in the evaluation of menstrual irregularities.
- Evaluating patients with suspected hypogonadism.
- 3. Predicting ovulation4. Evaluating infertility
- 5. Diagnosing pituitary disorders
- 6. In both males and females, primary hypogonadism results in an elevation of basal follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels

### **FSH** and LH LEVELS ELEVATED IN:

- Primary gonadal failure
   Complete testicular feminization syndrome.
- 3. Precocious puberty (either idiopathic or secondary to a central nervous system lesion) 4. Menopause (postmenopausal FSH levels are generally >40 IU/L)
- 5. Primary ovarian hypofunction in females
- 6. Primary hypogonadism in males

1. Normal or decreased FSH is seen in polycystic ovarian disease in females 2. FSH and LH are both decreased in failure of the pituitary or hypothalamus.

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)







# A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 pkrjainhealthcare@gmail.com

**NAME** : Mrs. MINAKSHI

AGE/ GENDER : 24 YRS/FEMALE **PATIENT ID** : 1702332

**COLLECTED BY** REG. NO./LAB NO. : 122412180012

REFERRED BY **REGISTRATION DATE** : 18/Dec/2024 12:52 PM BARCODE NO. **COLLECTION DATE** : 18/Dec/2024 12:56PM : 12506203 CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 18/Dec/2024 10:07PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

**Value** Unit **Biological Reference interval Test Name** 

### **PROLACTIN**

PROLACTIN: SERUM 18.21 ng/mL 3 - 25

by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)

1. Prolactin is secreted by the anterior pituitary gland and controlled by the hypothalamus.
2. The major chemical controlling prolactin secretion is dopamine, which inhibits prolactin secretion from the pituitary.

3. Physiological function of prolactin is the stimulation of milk production. In normal individuals, the prolactin level rises in response to physiologic stimuli such as sleep, exercise, nipple stimulation, sexual intercourse, hypoglycemia, postpartum period, and also is elevated in the newborn infant.

## **INCREASED (HYPERPROLACTEMIA):**

- 1.Prolactin-secreting pituitary adenoma (prolactinoma, which is 5 times more frequent in females than males). 2.Functional and organic disease of the hypothalamus.
- 3. Primary hypothyroidism.
- 4. Section compression of the pituitary stalk.
- 5. Chest wall lesions and renal failure.
- 6. Ectopic tumors
- 7.DRUGS:- Anti-Dopaminergic drugs like antipsychotic drugs, antinausea/antiemetic drugs, Drugs that affect CNS serotonin metabolism, serotonin receptors, or serotonin reuptake (anti-depressants of all classes, ergot derivatives, some illegal drugs such as cannabis), Antihypertensive drugs ,Opiates, High doses of estrogen or progesterone,anticonvulsants (valporic acid), anti-tuberculous medications (Isoniazid). SIGNIFICANCE:
- 1. In loss of libido, galactorrhea, oligomHyperprolactinemia often results enorrhea or amenorrhea, and infertility in premenopausal females. 2. Loss of libido, impotence, infertility, and hypogonadism in males. Postmenopausal and premenopausal women, as well as men, can also suffer from decreased muscle mass and osteoporosis.

- 3. In males, prolactin levels >13 ng/mL are indicative of hyperprolactinemia.
  4. In women, prolactin levels >27 ng/mL in the absence of pregnancy and postpartum lactation are indicative of hyperprolactinemia.
  5. Clear symptoms and signs of hyperprolactinemia are often absent in patients with serum prolactin levels <100 ng/mL.
  4. Miles to impresent to Measure levels of serum prolactin are not a reliable guide for determining whether a prolactin-producing pituitary adenoma is present, 5. Whereas levels >250 ng/mL are usually associated with a prolactin-secreting tumor. **CAUTION:**

Prolactin values that exceed the reference values may be due to macroprolactin (prolactin bound to immunoglobulin). Macroprolactin should be evaluated if signs and symptoms of hyperprolactinemia are absent, or pituitary imaging studies are not informative.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)







# A PIONEER DIAGNOSTIC CENTRE

**NAME** : Mrs. MINAKSHI

AGE/ GENDER : 24 YRS/FEMALE **PATIENT ID** : 1702332

**COLLECTED BY** REG. NO./LAB NO. : 122412180012

REFERRED BY **REGISTRATION DATE** : 18/Dec/2024 12:52 PM BARCODE NO. : 12506203 **COLLECTION DATE** : 18/Dec/2024 12:56PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 18/Dec/2024 10:07PM

**CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Value Unit **Biological Reference interval Test Name** 

## **PROGESTERONE**

PROGESTERONE: SERUM 18.32 ng/mL MALES: 0.21 - 2.10

by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY NON PREGNANT WOMEN MID FOLLICULAR PHASE: 0.29 -

MID LUTEAL PHASE: 5.11 -

18.78

PREGNANT WOMEN

FIRST TRIMESTER: 4.69 - 51.31 SECOND TRIMESTER: 19.24 -

45.55

# INTERPRETATION:

EXPECTED VALUES OF PROGESTERONE DURING PREGNANCY		
	UNITS (ng/mL)	
First trimester (0 - 12 Wweeks)	15.8 - 46.0	
Second trimester (13 - 28 Wweeks)	15.6 - 74.0	
Third trimester (29 - 40 Wweeks)	45.0 - 143.0	
Post Menopausal	< 1.40	

- 1. Progesterone is produced by the adrenal glands, corpus luteum, and placenta.
- 2. After ovulation, there is a significant rise in serum Progesterone levels as the corpus luteum begins To produce progesterone in increasing amounts. This causes changes in the uterus, preparing it for implantation of a fertilized egg. If implantation occurs, the trophoblast begins to secrete human chorionic gonadotropin, which maintains the corpus luteum and its secretion of progesterone. If there is no implantation, the corpus luteum degenerates and circulating progesterone levels decrease rapidly, reaching follicular phase levels about 4 days before the next menstrual period.

# The test is indicated for:

- 1. Ascertaining whether ovulation occurred in a menstrual cycle
- 2. Evaluation of placental function in pregnancy
- 3. Workup of some patients with adrenal or testicular tumors

### NOTF:

In patients receiving therapy with high biotin doses (ie, >5 mg/day), no specimen should be drawn until at least 8 hours after the last biotin administration.

\*\*\* End Of Report \*\*\*



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

